Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997;Évaluation des coûts opérationnels d'une campagne de masse préventive contre la méningite à méningocoque et la fièvre jaune au Sénégal, en 1997

Cahiers Sante

Volumn 13, Issue 4, 2003, Pages 215-223

  Da Silva, Alfred ^a   Du Châtelet, Isabelle Parent ^a   Gaye, Abou Beckr ^b   Dompnier, Jean Pierre ^c   Seck, Ibrahima ^d  

^a Assoc pour l'Aide a la Med Prev   (France)

^b Min de la S Pub/des Aff Social   (Senegal)

^c Min de la S Pub/des Aff Social   (Senegal)

^d NONE

Author keywords

Meningitis; Prevention; Vaccination; Yellow Fever

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; SOLVENT; VIRUS ANTIGEN; YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EPIDEMIC; EPIDEMIC MENINGITIS; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; INFECTION PREVENTION; INJECTION; MAJOR CLINICAL STUDY; MEDICAL FEE; RESOURCE ALLOCATION; RURAL AREA; SENEGAL; STAFF; TECHNIQUE; TRAINING; URBAN AREA; WORLD HEALTH ORGANIZATION; YELLOW FEVER; COST; ECONOMICS; HEALTH CARE COST; IMMUNOLOGY; PREVENTIVE HEALTH SERVICE; STATISTICS;

COSTS AND COST ANALYSIS; DISEASE OUTBREAKS; ECONOMICS; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; MENINGITIS, MENINGOCOCCAL; SENEGAL; YELLOW FEVER;

EID: 1542378380     PISSN: 11575999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Lapeyssonnie L. La méningite cérébrospinale en Afrique. Bull WHO 1963; 28 (suppl): 53-114.
2. Moore PS, Plikaytis BD, Bolan GA, et al. Detection of meningitis epidemics in Africa: a population-based analysis. Int J Epidemiol 1992; 21: 155-62.
3. Varaine F, Caugant DA, Riou JY, et al. Meningitis outbreaks and vaccination strategy. Trans R Soc Trop Med Hyg 1997; 91: 3-7.
4. Rioux JY, Djibo S, Sangare L, et al. A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull WHO 1996; 74: 181-7.
5. Response to epidemic meningitis in Africa, 1997. Wkly Epidemiol Rec 1997; 72: 313-8.
6. Thonnon J. Epidémie de fièvre jaune de Kaffrine. Rapport sur le fonctionnement technique de l'lnstitut Pasteur de Dakar, 1996. Dakar: Institut Pasteur, 1997: 26-8.
7. Veeken H, Ritmeijer K, Hausman B. Priority during a meningitis epidemic: vaccination or treatment? Bull WHO 1998; 76: 135-41.
8. Monath TP, Nasidi A. Should yellow fever vaccine be included in the Expanded Program of Immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg 1993; 48: 274-99.
9. Robbins JB, Towne DW, Gotschild EC, Schneerson R. «Love's labours lost»: failure to implement mass vaccination against group A meningococcal meningitis in sub-saharan Africa. Lancet 1997; 350: 880-2.
10. Collège des économistes de la santé. Recommandations de bonnes pratiques des méthodes d'évaluation économique des stratégies thérapeutiques. La lettre du Collège 1997; numéro spécial: 2-16.
11. Lecaillon J. Analyse microéconomique. Paris: Ed. Cujas, 1967.
12. Creese A, Parker D. Cost analysis in primary health care. A training manual for programme managers. Genève: WHO, 1994; 147 p.
13. Margerin J. Bases de la comptabilité analytique. Paris: Sedifor, les éditions d'organisation, 1991; 155 p.
14. Bellut S. La comptabilité par la maîtrise des coûts: conception à court objectif et analyse de la valeur. Paris: Ed Afnor, 1990; 277 p.
15. Gotschlich EC, Rey M, Triau R, Sparks KJ. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest 1972; 51: 89-96.
16. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration in clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2: 114-8.